CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors

Chimeric antigen receptor (CAR) T-cell therapy targeting solid tumors has stagnated as a result of tumor heterogeneity, immunosuppressive microenvironments, and inadequate intratumoral T cell trafficking and persistence. Early (≤3 days) intratumoral presentation of CAR T cells post-treatment is a su...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Linchun, Tao, Haipeng, Karachi, Aida, Long, Yu, Hou, Alicia Y., Na, Meng, Dyson, Kyle A., Grippin, Adam J., Deleyrolle, Loic P., Zhang, Wang, Rajon, Didier A., Wang, Qiong J., Yang, James C., Kresak, Jesse L., Sayour, Elias J., Rahman, Maryam, Bova, Frank J., Lin, Zhiguo, Mitchell, Duane A., Huang, Jianping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6728370/
https://www.ncbi.nlm.nih.gov/pubmed/31488817
http://dx.doi.org/10.1038/s41467-019-11869-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6728370/
https://www.ncbi.nlm.nih.gov/pubmed/31488817
http://dx.doi.org/10.1038/s41467-019-11869-4

Ejemplares similares